$PODD

Analysts' consensus for Insulet (PODD) is 'Moderate Buy' with 13 'Strong Buy' ratings, 2 'Moderate Buy', 11 'Hold', and 1 'Strong Sell'. Citigroup analyst Joanne Wuensch maintained a 'Hold' rating with a $150 price target, a 3.1% upside. The mean price target is $172.46, an 18.6% premium, while the highest target is $275, an 89.1% upside.

Pomerantz LLP filed a class action lawsuit against Insulet Corporation (NASDAQ: PODD) and certain officers, alleging securities violations. The suit covers investors who acquired Insulet securities between February 21, 2025, and May 26, 2026. The complaint claims Insulet made false statements about its manufacturing controls and product safety. Insulet's stock price fell 6.88% and 5.07% following two voluntary medical device corrections in March and May 2026, respectively.

Insider trading activity reported for US public companies includes significant purchases and sales. ADAR1 Capital bought 1.03M Tenax Therapeutics (TENX) shares for $1.81M. Kenneth Courtis acquired 15K Alpha Metallurgical (AMR) shares for $3.16M. Rex Geveden bought 5K TTM Technologies (TTMI) shares for $524.5K. Ashley McEvoy, CEO of Insulet (PODD), purchased 1.1K shares for $162.2K. Notable sales include James Wirth selling IHT shares for $1.82B, Alexander Karp selling 492K Palantir (PLTR) shares

Insulet CEO Ashley McEvoy purchased $160,000 in shares following a 55% stock decline. The company, with a $10.3B market cap and $3.1B TTM revenue, reported 23% sales growth in its latest quarter. McEvoy's purchase is seen as a bullish signal, as insider buying often predicts higher share prices. The company aims to improve user retention for its Omnipod platform and expects 21% revenue growth for the fiscal year.

McEvoy Ashley (President and CEO) purchased 1,100 shares of INSULET CORP (PODD) at $147.47 ($0.16M total) on 2026-08-21.

Bernstein Liebhard LLP said a shareholder filed a securities class action against Insulet Corp. (NASDAQ: PODD) for investors who bought shares between Feb. 21, 2025 and May 26, 2026. The suit alleges materially false or misleading statements and omissions about operations, growth prospects, and financial stability, leading to inflated prices and losses. Lead plaintiff papers due Aug. 31, 2026.

Pomerantz LLP said it filed a class action in Massachusetts federal court against Insulet Corp (NASDAQ: PODD) and certain officers. The suit covers purchases of Insulet securities from Feb 21, 2025 to May 26, 2026, alleging federal securities law violations. Insulet disclosed voluntary medical device corrections in March 2026 and May 2026, after which PODD shares fell $16.23 (6.88%) and $7.79 (5.07%).

Alpha Wealth Funds’ Q2 2026 “Insiders Fund” letter cited Insulet Corp (PODD) and said the fund fell 1.45% in June, up 8.43% in Q2, and 0.75% YTD versus S&P 500 -0.95%, 15.2%, 9.98%. PODD closed Aug 12 at $161.28, with -11.78% one-month and -54.06% 52-week returns. The letter referenced Omnipod 5 corrections tied to cannula tear risk and noted insider share purchases.

Insulet (PODD) reported Q2 2026 revenue of $801.7M, up 22.7% constant currency and above guidance. Adjusted EPS was $1.66, up 41.5%. U.S. Omnipod revenue was $544.1M, and international was $251.8M. Management revised U.S. full-year Omnipod growth to 17% to 19% and raised international to 30% to 32%, citing weaker type 2 retention.

Simply Wall St reports Insulet (PODD) shares fell 15% to about $141 after its latest quarterly results. Revenue was $802m in line with forecasts, while statutory profit was $1.37 per share. Analysts now expect 2026 revenue of $3.29b and EPS $6.17, with the consensus price target cut 27% to $172.